|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
GWAS on family history of Alzheimer's disease.
|
29777097 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
|
21460841 |
2011 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.
|
30617256 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of Alzheimer's disease.
|
22832961 |
2012 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
BEFREE |
It also is necessary to investigate further the interaction between Lu/B-CAM and laminin a5 in pathological processes, including sickle cell disease and cancer.
|
16546822 |
2005 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
BEFREE |
We investigated the molecular mechanisms responsible for the Lu/BCAM-mediated abnormal RBC adhesion to laminin in sickle cell disease (SCD) and HS.
|
20655789 |
2010 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
BEFREE |
The Lu/BCAM adhesion glycoproteins were first identified as laminin-10/11 erythroid receptors involved in RBC adhesion to endothelium in sickle cell anemia.
|
18948049 |
2008 |
|
Anemia, Sickle Cell
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Red blood cells from patients with sickle cell disease (SS RBC) adhere to laminin and over-express the high-affinity laminin receptor basal cell adhesion molecule/Lutheran protein (B-CAM/LU).
|
14755370 |
2004 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
LHGDN |
Red blood cells from patients with sickle cell disease (SS RBC) adhere to laminin and over-express the high-affinity laminin receptor basal cell adhesion molecule/Lutheran protein (B-CAM/LU).
|
14755370 |
2004 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
BEFREE |
Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease.
|
20562314 |
2010 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Five human bladder cancer (E6, RT4, TSGH8301, TCCSUP and J82), one stable mouse fibroblast cell line (NIH-Lu) expressing Lu/BCAM transgene and sixty human uroepithelial carcinoma specimens were analyzed by real-time PCR, immunohistochemistry (IHC), immunofluorescence (IFA) staining, Western blotting and promoter luciferase assay for Lu/BCAM, respectively.
|
28841878 |
2017 |
|
BLOOD GROUP--LUTHERAN NULL
|
0.100 |
CausalMutation
|
phenotype |
CLINVAR |
|
|
|
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The non-BCAM (Breast cancer awareness month) group were screened from February to September 2016 and the BCAM group during October 2016.
|
28351284 |
2018 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results show that CD239 is a promising antigen for ADC-based breast cancer therapy.
|
29700410 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
However, the function of BCAM in carcinogenesis is poorly understood.
|
24223164 |
2013 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
This study was performed to investigate the role and downstream signaling pathway of Lu/BCAM in human bladder tumorigenesis.
|
28841878 |
2017 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Another carcinogenesis-associated antigen is Lutheran or BCAM (basal cell adhesion molecule), a surface glycoprotein that acts as a receptor for the extracellular matrix protein, laminin.
|
23168236 |
2013 |
|
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of DARC and BCAM were evaluated by quantitative real-time PCR (qPCR) in a set of 18 normal thyroid tissues (NT), 15 follicular adenomas (FTA), 17 follicular carcinomas (FTC), and 122 papillary thyroid carcinomas (PTC), including 78 classical (CVPTC) and 44 follicular variant (FVPTC).
|
23168236 |
2013 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Five human bladder cancer (E6, RT4, TSGH8301, TCCSUP and J82), one stable mouse fibroblast cell line (NIH-Lu) expressing Lu/BCAM transgene and sixty human uroepithelial carcinoma specimens were analyzed by real-time PCR, immunohistochemistry (IHC), immunofluorescence (IFA) staining, Western blotting and promoter luciferase assay for Lu/BCAM, respectively.
|
28841878 |
2017 |
|
Chronic myeloproliferative disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further work is required to determine the role of the increased Lu/BCAM adhesion to the endothelium in the development of thrombosis in MPN of all genotypes.
|
29756283 |
2018 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two new members of the Ig superfamily, the Lutheran (Lu) blood group glycoprotein and the B-cell adhesion molecule (B-CAM) epithelial cancer antigen, have been recently cloned from human placenta and colon cancer HT29 cell line, respectively.
|
8781446 |
1996 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The role of BCAM in the interaction of KRAS-mutant colorectal cancer cells with TME cells was investigated by adhesion assays.
|
27143691 |
2016 |
|
Follicular adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
When we compared benign (NT and FTA) versus malignant samples (FTC, CVPTC and FVPTC) we observed a significant decrease of DARC and BCAM relative expression in malignant cases.
|
23168236 |
2013 |
|
Follicular thyroid carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
When we compared benign (NT and FTA) versus malignant samples (FTC, CVPTC and FVPTC) we observed a significant decrease of DARC and BCAM relative expression in malignant cases.
|
23168236 |
2013 |
|
Hereditary spherocytosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
On the other hand, we showed that increased Lu/BCAM-mediated HS RBC adhesion to laminin was independent of Lu/BCAM phosphorylation.
|
20655789 |
2010 |